Editorials

Teratogenicity of antiepileptic drugs

BMJ 2006; 333 doi: http://dx.doi.org/10.1136/bmj.38961.437639.BE (Published 21 September 2006) Cite this as: BMJ 2006;333:615
  1. David P Breen ([email protected]), foundation year 2 doctor in colorectal surgery,
  2. Richard J Davenport, consultant neurologist
  1. Department of Colorectal Surgery, Western General Hospital, Edinburgh EH4 2XU
  2. Department of Clinical Neurosciences, Western General Hospital, Edinburgh EH4 2XU

    Women should consider stopping, minimising, or switching drugs before pregnancy

    Prescribing for women with epilepsy is complicated by the potential teratogenicity of antiepileptic drugs. Current guidelines recommend that the most effective drug should be chosen before conception and prescribed at its lowest effective dose, ideally as monotherapy.12 But which antiepileptic drug is safest in pregnancy?

    Early research on the safety of antiepileptic drugs in pregnancy was unreliable. Several countries set up pregnancy registries in the late 1990s, and data from these registries are now appearing.

    To date the UK Epilepsy and Pregnancy Registry has recruited more than 3500 women, of whom 72% were given antiepileptic monotherapy. The overall rate of major congenital malformation in women given antiepileptic drugs during pregnancy was 4.2%, compared with 3.5% in women with epilepsy who were not given such drugs.3 By three months of age, infants exposed to sodium valproate monotherapy during gestation had the highest frequency of major congenital malformation (6.2%), confirming similar findings from an Australian register.4 Lamotrigine monotherapy was associated with a 3.2% …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe